Chemomab Therapeutics Ltd ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 31 Dec 2025
Net Income -$9MTTM through 31 Dec 2025
Free Cash Flow -$11.2MTTM through 31 Dec 2025
Margins
| Current |
|---|
Returns
-72.9%ROE
-65.1%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio9.08x
Net Debt-$10.4Mnet cash position
Cash & Equivalents$7.6M
Quality Metrics
Altman Z-Score-29.96
Piotroski F-Score3 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPSFY2025: $0.02
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Biopharmaceutical Research and Development | $0 | View detailsPreparing for potential initiation of a nebokitug Phase 3 trial in primary sclerosing cholangians (PSC) following alignment with the FDA on a single pivotal trial design. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.